-
Je něco špatně v tomto záznamu ?
Effect of Erythropoietin on the Expression of Murine Transferrin Receptor 2
B. Berezovsky, M. Báječný, J. Frýdlová, I. Gurieva, DW. Rogalsky, P. Přikryl, V. Pospíšil, E. Nečas, M. Vokurka, J. Krijt
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
PROGRES Q26
Univerzita Karlova v Praze
SVV 260519
Univerzita Karlova v Praze
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
34360974
DOI
10.3390/ijms22158209
Knihovny.cz E-zdroje
- MeSH
- cytokiny genetika metabolismus MeSH
- erythropoetin farmakologie MeSH
- erytroblasty účinky léků metabolismus MeSH
- exozómy metabolismus MeSH
- hepcidiny genetika metabolismus MeSH
- játra metabolismus MeSH
- kultivované buňky MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- receptory transferinu genetika metabolismus MeSH
- slezina metabolismus MeSH
- svalové proteiny genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Erythropoietin (EPO) downregulates hepcidin expression to increase the availability of iron; the downregulation of hepcidin is mediated by erythroferrone (ERFE) secreted by erythroblasts. Erythroblasts also express transferrin receptor 2 (TFR2); however, the possible role of TFR2 in hepcidin downregulation is unclear. The purpose of the study was to correlate liver expression of hepcidin with the expression of ERFE and TFR2 in murine bone marrow and spleen at 4, 16, 24, 48, 72 and 96 h following administration of a single dose of EPO. Splenic Fam132b expression increased 4 h after EPO injection; liver hepcidin mRNA was decreased at 16 h. In the spleen, expression of TFR2 and transferrin receptor (TFR1) proteins increased by an order of magnitude at 48 and 72 h after EPO treatment. The EPO-induced increase in splenic TFR2 and TFR1 was associated with an increase in the number of Tfr2- and Tfr1-expressing erythroblasts. Plasma exosomes prepared from EPO-treated mice displayed increased amount of TFR1 protein; however, no exosomal TFR2 was detected. Overall, the results confirm the importance of ERFE in stress erythropoiesis, support the role of TFR2 in erythroid cell development, and highlight possible differences in the removal of TFR2 and TFR1 from erythroid cell membranes.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025286
- 003
- CZ-PrNML
- 005
- 20220222112943.0
- 007
- ta
- 008
- 211013s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms22158209 $2 doi
- 035 __
- $a (PubMed)34360974
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Berezovsky, Betty, $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic $d 1994- $7 xx0269766
- 245 10
- $a Effect of Erythropoietin on the Expression of Murine Transferrin Receptor 2 / $c B. Berezovsky, M. Báječný, J. Frýdlová, I. Gurieva, DW. Rogalsky, P. Přikryl, V. Pospíšil, E. Nečas, M. Vokurka, J. Krijt
- 520 9_
- $a Erythropoietin (EPO) downregulates hepcidin expression to increase the availability of iron; the downregulation of hepcidin is mediated by erythroferrone (ERFE) secreted by erythroblasts. Erythroblasts also express transferrin receptor 2 (TFR2); however, the possible role of TFR2 in hepcidin downregulation is unclear. The purpose of the study was to correlate liver expression of hepcidin with the expression of ERFE and TFR2 in murine bone marrow and spleen at 4, 16, 24, 48, 72 and 96 h following administration of a single dose of EPO. Splenic Fam132b expression increased 4 h after EPO injection; liver hepcidin mRNA was decreased at 16 h. In the spleen, expression of TFR2 and transferrin receptor (TFR1) proteins increased by an order of magnitude at 48 and 72 h after EPO treatment. The EPO-induced increase in splenic TFR2 and TFR1 was associated with an increase in the number of Tfr2- and Tfr1-expressing erythroblasts. Plasma exosomes prepared from EPO-treated mice displayed increased amount of TFR1 protein; however, no exosomal TFR2 was detected. Overall, the results confirm the importance of ERFE in stress erythropoiesis, support the role of TFR2 in erythroid cell development, and highlight possible differences in the removal of TFR2 and TFR1 from erythroid cell membranes.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a cytokiny $x genetika $x metabolismus $7 D016207
- 650 _2
- $a erytroblasty $x účinky léků $x metabolismus $7 D004900
- 650 _2
- $a erythropoetin $x farmakologie $7 D004921
- 650 _2
- $a exozómy $x metabolismus $7 D055354
- 650 _2
- $a hepcidiny $x genetika $x metabolismus $7 D064451
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a svalové proteiny $x genetika $x metabolismus $7 D009124
- 650 _2
- $a receptory transferinu $x genetika $x metabolismus $7 D011990
- 650 _2
- $a slezina $x metabolismus $7 D013154
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Báječný, Martin $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Frýdlová, Jana $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Gurieva, Iuliia $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Rogalsky, Daniel Wayne $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Přikryl, Petr $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Pospíšil, Vít $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Nečas, Emanuel $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Vokurka, Martin $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 700 1_
- $a Krijt, Jan $u Institute of Pathophysiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 128 53 Prague, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 15 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34360974 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20220222112940 $b ABA008
- 999 __
- $a ok $b bmc $g 1714371 $s 1145793
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 15 $e 20210730 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a PROGRES Q26 $p Univerzita Karlova v Praze
- GRA __
- $a SVV 260519 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20211013